Maze Therapeutics, Inc.·4

Sep 2, 6:30 PM ET

Tahir Misbah 4

4 · Maze Therapeutics, Inc. · Filed Sep 2, 2025

Insider Transaction Report

Form 4
Period: 2025-09-02
Tahir Misbah
Chief Financial Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    2025-09-02+325,000325,000 total
    Exercise: $15.32Exp: 2035-09-01Common Stock (325,000 underlying)
Footnotes (1)
  • [F1]The option shall vest as to 1/4th of the total award on September 2, 2026, and thereafter shall vest as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

Documents

1 file
  • 4
    form4-09022025_100947.xmlPrimary